<DOC>
	<DOCNO>NCT03049449</DOCNO>
	<brief_summary>Background : - Improved treatment variety treatment-resistant , CD30-expressing malignancy include Hodgkin lymphoma , anaplastic large cell lymphoma , CD30- express lymphoma need . - T cell genetically modify express chimeric antigen receptor ( CARs ) specifically target malignancy-associated antigen . - Autologous T cell genetically modify express CARs target B-cell antigen CD19 cause complete remission small number patient lymphoma . These result demonstrate CAR-expressing T cell anti-lymphoma activity human . - CD30 expression easily detect immunohistochemistry lymphoma cell , allow selection CD30-expressing malignancy treatment . - CD30 know express normal cell except small number activate lymphocytes decidual cell pregnant uterus . - We construct novel fully-human anti-CD30 CAR specifically recognize CD30-expressing target cell vitro eradicate CD30-expressing tumor mouse . - This particular CAR test human . - Possible toxicity include cytokine-associated toxicity fever , hypotension , neurological toxicity . Elimination small number normal activate lymphocyte possible , unknown toxicity also possible . Objectives : Primary -Determine safety feasibility administer T-cells express novel fullyhuman anti-CD30 CAR patient advance CD30-expresssing lymphoma . Eligibility : - Patients must Hodgkin lymphoma , anaplastic large cell lymphoma , peripheral T-cell lymphoma otherwise specify , diffuse large B-cell lymphoma otherwise specify , primary mediastinal B-cell lymphoma , grey zone lymphoma , enteropathyassociated T-cell lymphoma , extranodal NK/T-cell lymphoma , nasal type - Patients must malignancy measurable CT scan large diameter least 1.5 cm possess increased metabolic activity detectable PET scan . Alternatively patient lymphoma detect flow cytometry bone marrow eligible . - Patients must creatinine 1.4 mg/dL less normal cardiac ejection fraction . - An ECOG performance status 0-1 require . - No active infection allow include history HIV , hepatitis B , hepatitis C. Patients must seronegative CMV blood PCR . - Absolute neutrophil count great equal 1000/micro L , platelet count great equal 45,000/micro L , hemoglobin great equal 8g/dL - Serum ALT AST less equal 3 time upper limit institutional normal unless liver involvement malignancy demonstrate . - At least 14 day must elapse time prior systemic treatment ( include corticosteroid ) initiation protocol enrollment . - Clear CD30 expression must detect 75 % malignant cell either bone marrow lymphoma mass flow cytometry immunohistochemistry . The patient malignancy need assess CD30 expression flow cytometry immunohistochemistry perform NIH . If unstained , paraffin-embedded bone marrow lymphoma section available prior biopsy , use determine CD30 expression immunohistochemistry ; otherwise , patient need come NIH biopsy determine CD30 expression . The sample CD30 expression come biopsy obtain time enrollment , unless patient receive prior anti-CD30 monoclonal antibody , case sample must come biopsy follow completion recent anti-CD30 monoclonal antibody treatment . - Eligible patient Hodgkin lymphoma must fulfill one follow criterion : 1 ) receive two prior therapy , one must autologous stem cell transplant , 2 ) receive three prior line therapy . Eligible patient list peripheral T cell lymphomas non-Hodgkin lymphoma must receive two line prior therapy , least one must contain cytotoxic chemotherapyPatients diffuse large B-cell lymphoma primary mediastinal B-cell lymphoma must receive 2 prior treatment regimen least 1 included anthracycline anti-CD20 monoclonal antibody . - Patients never allogeneic hematopoietic stem cell transplant well patient HLA-matched sibling 8/8 HLA-matched unrelated donor hematopoietic stem cell transplant potentially eligible . - Women pregnant plan become pregnant excluded . Due risk damage normal uterine tissue secretory phase menstruation , w ... ...</brief_summary>
	<brief_title>T Cells Expressing Fully-Human Anti-CD30 Chimeric Antigen Receptor Treating CD30-Expressing Lymphomas</brief_title>
	<detailed_description>Background : - Improved treatment variety treatment-resistant , CD30-expressing malignancy include Hodgkin lymphoma , anaplastic large cell lymphoma , CD30- express lymphoma need . - T cell genetically modify express chimeric antigen receptor ( CARs ) specifically target malignancy-associated antigen . - Autologous T cell genetically modify express CARs target B-cell antigen CD19 cause complete remission small number patient lymphoma . These result demonstrate CAR-expressing T cell anti-lymphoma activity human . - CD30 expression easily detect immunohistochemistry lymphoma cell , allow selection CD30-expressing malignancy treatment . - CD30 know express normal cell except small number activate lymphocytes decidual cell pregnant uterus . - We construct novel fully-human anti-CD30 CAR specifically recognize CD30-expressing target cell vitro eradicate CD30-expressing tumor mouse . - This particular CAR test human . - Possible toxicity include cytokine-associated toxicity fever , hypotension , neurological toxicity . Elimination small number normal activate lymphocyte possible , unknown toxicity also possible . Objectives : Primary -Determine safety feasibility administer T-cells express novel fullyhuman anti-CD30 CAR patient advance CD30-expresssing lymphoma . Eligibility : - Patients must Hodgkin lymphoma , anaplastic large cell lymphoma , peripheral T-cell lymphoma otherwise specify , diffuse large B-cell lymphoma otherwise specify , primary mediastinal B-cell lymphoma , grey zone lymphoma , enteropathyassociated T-cell lymphoma , extranodal NK/T-cell lymphoma , nasal type - Patients must malignancy measurable CT scan large diameter least 1.5 cm possess increased metabolic activity detectable PET scan . Alternatively patient lymphoma detect flow cytometry bone marrow eligible . - Patients must creatinine 1.4 mg/dL less normal cardiac ejection fraction . - An ECOG performance status 0-1 require . - No active infection allow include history HIV , hepatitis B , hepatitis C. Patients must seronegative CMV blood PCR . - Absolute neutrophil count great equal 1000/micro L , platelet count great equal 45,000/micro L , hemoglobin great equal 8g/dL - Serum ALT AST less equal 3 time upper limit institutional normal unless liver involvement malignancy demonstrate . - At least 14 day must elapse time prior systemic treatment ( include corticosteroid ) initiation protocol enrollment . - Clear CD30 expression must detect 75 % malignant cell either bone marrow lymphoma mass flow cytometry immunohistochemistry . The patient malignancy need assess CD30 expression flow cytometry immunohistochemistry perform NIH . If unstained , paraffin-embedded bone marrow lymphoma section available prior biopsy , use determine CD30 expression immunohistochemistry ; otherwise , patient need come NIH biopsy determine CD30 expression . The sample CD30 expression come biopsy obtain time enrollment , unless patient receive prior anti-CD30 monoclonal antibody , case sample must come biopsy follow completion recent anti-CD30 monoclonal antibody treatment . - Eligible patient Hodgkin lymphoma must fulfill one follow criterion : 1 ) receive two prior therapy , one must autologous stem cell transplant , 2 ) receive three prior line therapy . Eligible patient list peripheral T cell lymphomas non-Hodgkin lymphoma must receive two line prior therapy , least one must contain cytotoxic chemotherapyPatients diffuse large B-cell lymphoma primary mediastinal B-cell lymphoma must receive 2 prior treatment regimen least 1 included anthracycline anti-CD20 monoclonal antibody . - Patients never allogeneic hematopoietic stem cell transplant well patient HLA-matched sibling 8/8 HLA-matched unrelated donor hematopoietic stem cell transplant potentially eligible . - Women pregnant plan become pregnant excluded . Due risk damage normal uterine tissue secretory phase menstruation , woman menstrual period last six month exclude . Participating woman must serum FSH great 22 units/Liter estradiol level &lt; 10 pg/mL take progestin-containing drug . If woman currently achieve effective menstrual suppression Lupron similar gonadotropin-releasing hormone ( GnRH ) analogues menstrual period last six month stable dose GnRH analogue , may participate trial without meet FSH serum estradiol criterion continuation GnRH analogue trial least 3 month follow final CAR T-cell infusion . All pre-menopausal woman ask consultation NIH gynecology prior trial participation . Design : - This phase I dose-escalation trial . - Patients undergo leukapheresis . - T cell obtain leukapheresis genetically modify express anti-CD30 CAR . - Patients receive lymphocyte-depleting chemotherapy condition regimen intent enhance activity infuse anti-CD30 CAR-expressing T cell . - The chemotherapy condition regimen cyclophosphamide 300 mg/m2 daily 3 day fludarabine 30 mg/m2 daily 3 day . Fludarabine give day cyclophosphamide . - Two day chemotherapy end , patient receive infusion anti-CD30-CAR-expressing T cell . - The initial dose level dose-escalation trial 0.3x106 CAR+ T cells/kg recipient bodyweight . - The cell dose administer escalated maximum tolerate dose determine . - Following T-cell infusion , mandatory 9-day inpatient hospitalization monitor toxicity . - Outpatient follow-up plan 2 week 1 , 2 , 3 , 6 , 9 , 12 month CAR T-cell infusion . Long-term gene-therapy follow-up consist yearly visit doctor near patient home 4 year yearly telephone contact 10 additional year require . - Re-enrollment allow small number subject .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : Malignancy Criteria : Patients must Hodgkin lymphoma , anaplastic large cell lymphoma , peripheral Tcell lymphoma otherwise specify , diffuse large Bcell lymphoma otherwise specify , primary mediastinal Bcell lymphoma , grey zone lymphoma , enteropathyassociated Tcell lymphoma , extranodal NK/Tcell lymphoma , nasal type Clear CD30 expression must detect 75 % malignant cell either bone marrow lymphoma mass flow cytometry immunohistochemistry . The patient malignancy need assess CD30 expression flow cytometry immunohistochemistry perform NIH . If unstained , paraffinembedded bone marrow lymphoma section available prior biopsy , use determine CD30 expression immunohistochemistry ; otherwise , patient need come NIH biopsy determine CD30 expression . The sample CD30 expression come biopsy obtain time enrollment , unless patient receive prior antiCD30 monoclonal antibody , case sample must come biopsy follow completion recent antiCD30 monoclonal antibody treatment . Eligible patient Hodgkin lymphoma must fulfill one follow criterion : 1 ) receive two prior therapy , one must autologous stem cell transplant , 2 ) receive three prior line therapy . Eligible patient list peripheral T cell lymphoma nonHodgkin lymphoma must receive two line prior therapy , least one must contain cytotoxic chemotherapy . Patients diffuse large Bcell lymphoma primary mediastinal Bcell lymphoma must receive 2 prior treatment regimen least 1 included anthracycline antiCD20 monoclonal antibody . Patients must measurable malignancy define least one criterion . Lymphoma mass measurable ( minimum 1.5 cm large diameter ) CT scan require unless bone marrow lymphoma detectable . For lymphoma mass count measurable malignancy , must abnormally increased metabolic activity assess positron emission tomography ( PET ) scan . For lymphoma bone marrow involvement , mass necessary , mass present , bone marrow malignancy must detectable flow cytometry . Other Greater equal 18 year age less equal age 73 . Able understand sign Informed Consent Document . Clinical performance status ECOG 01 Room air oxygen saturation 92 % great Male patient must willing practice birth control time enrollment study four month follow final CAR Tcell infusion . Premenopausal patient ( female patient menstrual period within last year ) must willing practice birth control time enrollment one year follow final CAR T cell infusion . Women childbearing potential must negative pregnancy test potentially dangerous effect preparative chemotherapy fetus infant . Women childbearing potential defined woman except woman postmenopausal hysterectomy . Postmenopausal define woman age 55 menstrual period least 1 year . For safety reason woman must menstrual period six month prior enrollment . A menstrual period define vaginal bleeding spot last one day . Participating woman must serum FSH great 22 units/Liter serum estradiol level &lt; 10 pg/mL take progestincontaining drug . If woman currently achieve effective menstrual suppression Lupron similar gonadotropinreleasing hormone ( GnRH ) analogues menstrual period last six month stable dose GnRH analogue , may participate trial without meet FSH serum estradiol criterion continuation GnRH analogue trial least 3 month follow final CAR Tcell infusion . All premenopausal woman ask consultation NIH gynecology prior trial participation . Seronegative HIV antibody . ( The experimental treatment evaluate protocol depends intact immune system . Patients HIV seropositive decrease immune competence thus less responsive experimental treatment susceptible toxicity . ) Patients known history hepatitis B hepatitis C eligible due risk reactivation hepatitis possible immunosuppression due antiCD30 CAR Tcells chemotherapy administer protocol . Seronegative HTLV1 . Negative hepatitis B surface antigen . Positive hepatitis B test evaluate confirmatory test ; confirmatory test negative , patient enrol . Patients known history hepatitis B eligible . Seronegative hepatitis C antibody unless antigen negative . If hepatitis C antibody test positive , patient must test presence RNA RTPCR HCV RNA negative . Patients known history hepatitis C eligible . Seronegative CMV JC virus blood PCR . Absolute neutrophil count great equal 1000/mm3 without support filgrastim growth factor . Platelet count great equal 45,000/mm3 without transfusion support Hemoglobin great 8.0 g/dl . Less 5 % malignant cell peripheral blood leukocyte Serum ALT AST less equal 3 time upper limit institutional normal unless liver involvement malignancy demonstrate . Serum creatinine less equal 1.4 mg/dL . Total bilirubin less equal 2.0 mg/dl . At least 14 day must elapse since prior systemic therapy prior apheresis prior initiation chemotherapy ( include systemic corticosteroid dose ) . Because protocol require collection autologous blood cell leukapheresis order prepare CAR T cell , systemic antimalignancy therapy include systemic corticosteroid therapy dose allow within 14 day prior required leukapheresis . NOTE : Because long halflife potential affect CAR Tcells , 30 day must elapse time administration antiPD1 antiPDL1 antibody agent opinion PI stimulate immune activity infusion CAR Tcells . Normal cardiac ejection fraction ( great equal 55 % echocardiography ) evidence hemodynamically significant pericardial effusion determine echocardiogram within 4 week start treatment protocol . Patients must take corticosteroid include prednisone , dexamethasone corticosteroid 14 day apheresis CAR Tcell infusion . Patients must also take corticosteroid dose high 5 mg/day prednisone equivalent time CAR T cell infusion . Patients must willing undergo endotracheal intubation , mechanical ventilation , dialysis , CPR , electrical defibrillation . Patients must willing receive vasopressor drug standard intensive care unit intervention . Any living must amend allow intervention patient eligible . Patients treat protocol geneticallymodified Tcells NIH potentially eligible condition : At least 6 month elapse since last geneticallymodified Tcell therapy patient receive evidence replicationcompetent retrovirus ( evidence must provide prior NIH genetherapy protocol Principal Investigator ) persist geneticallymodified T cell detectable patient blood ( evidence must provide prior NIH genetherapy protocol Principal Investigator ) . Additional Inclusion Criteria Pertinent Only Patients Prior Allogeneic Transplantation : Recipients must receive HLAidentical sibling allogeneic hematopoietic stem cell transplant 8/8matched ( HLAA , B , C , DR ) unrelated donor ( URD ) alloHSCT eligible CD30+ lymphoma Donor T cell engraftment alloHSCT ( &gt; 90 % donor chimerism Tcell compartment time protocol enrollment ) . Patients must least 90 day posttransplant . Patients must systemic immunosuppressive drug include corticosteroid dose least 28 day prior protocol enrollment must remain immunosuppressive drug enrol protocol . Patients must take systemic steroid 14 day prior apheresis initiation chemotherapy . Topical corticosteroid preparation apply skin solution , cream , ointment allow . Inhaled corticosteroid allow , corticosteroid eye drop allow . Prior DLIs necessary . Either evidence GVHD minimal clinical evidence acute GVHD chronic GVHD systemic immunosuppressive therapy least 28 day . Minimal clinical evidence acute GVHD define grade 0 I acute GVHD 109 Minimal evidence chronic GVHD define mild global score chronic GVHD ( defined 2005 NIH consensus project ) chronic GVHD .107 Subjects disease control stage I acute GVHD mild global score chronic GVHD local topical cutaneous steroid eligible enrollment . EXCLUSION CRITERIA : Patients require urgent therapy due tumor mass effect spinal cord compression . Patients lymphoma mass 10.0 cm large long diameter eligible . Patients active hemolytic anemia . Patients currently take medication systemic anticoagulation aspirin eligible . Patients second malignancy addition lymphoma eligible second malignancy require treatment ( include maintenance therapy ) within past 4 year complete remission . There two exception criterion : successfully treat nonmetastatic basal cell squamous cell skin carcinoma . Women childbearing potential pregnant breastfeed potentially dangerous effect preparative chemotherapy fetus infant . Women childbearing potential defined woman except woman postmenopausal hysterectomy . Postmenopausal define woman age 55 menstrual period least 1 year . Active uncontrolled systemic infection ( defined infection cause fever infection require intravenous antibiotic intravenous antibiotic administer less 72 hour ) ; active coagulation disorder major uncontrolled medical illness cardiovascular , respiratory , endocrine , renal , gastrointestinal , genitourinary immune system ; history myocardial infarction ; history ventricular tachycardia ventricular fibrillation ; active cardiac arrhythmia ( Active atrial fibrillation allow , resolve atrial fibrillation allow . ) ; active obstructive restrictive pulmonary disease ; active autoimmune disease rheumatoid arthritis . Patients see screen appointment enrol protocol hospitalize within 7 day prior screen appointment date protocol enrollment . Any form primary immunodeficiency ( Severe Combined Immunodeficiency Disease ) . Systemic corticosteroid therapy dose allow within 14 day prior required leukapheresis , initiation conditioning chemotherapy regimen . Corticosteroid cream , ointment , eye drop allow . History severe immediate hypersensitivity reaction agent use study . Patients current CNS involvement malignancy ( either image cerebrospinal fluid involvement biopsyproven ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>73 Years</maximum_age>
	<verification_date>February 16, 2017</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>Adoptive T Cell Therapy</keyword>
	<keyword>T-cell infusion</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Immunohistochemistry</keyword>
</DOC>